Fulcrum Therapeutics
FULC
108 hedge funds and large institutions have $930M invested in Fulcrum Therapeutics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 38 reducing their positions, and 22 closing their positions.
277% more call options, than puts
Call options by funds: $5.89M | Put options by funds: $1.56M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
41% more capital invested
Capital invested by funds: $657M → $930M (+$273M)
2.5% more ownership
Funds ownership: 94.63% → 97.13% (+2.5%)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 110 → 108 (-2)
24% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$48.9M |
| 2 |
Morgan Stanley
New York
|
+$14.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.46M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.37M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$15.3M |
| 2 |
Two Sigma Investments
New York
|
-$7.13M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$5.62M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.49M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.31M |
FULC Hedge Fund Activity: Q1 2022 in Review
108 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2022, worth a combined $930M — up 41% from $657M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of FULC and 21 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 29 added.
The largest buyer was Cowen and Company, opening a new position worth an estimated $48.9M. The largest seller was Holocene Advisors, exiting entirely with an estimated $15.3M sold.
- 108 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2022, down from 110 in Q4 2021.
- Funds reported $930M of Fulcrum Therapeutics stock for Q1 2022, up 41% quarter-over-quarter.
- 21 funds opened new Fulcrum Therapeutics positions in Q1 2022 and 22 closed out, a net change of -1 holder.
- The largest Fulcrum Therapeutics buyer in Q1 2022 was Cowen and Company, an estimated $48.9M added.
- The largest Fulcrum Therapeutics seller in Q1 2022 was Holocene Advisors, an estimated $15.3M sold.
Based on aggregated 13F filings for Q1 2022.